One hundred years of drug regulation:where do we go from here?

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 255-273

  Woosley, Raymond L ^a  

^a AZCERT Inc and NDA Partners LLC   (United States)

Author keywords

critical path; regulatory science; US Food and Drug Administration

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL;

BIOEQUIVALENCE; CLINICAL PHARMACOLOGY; DECISION MAKING; DRUG DEVELOPMENT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; HUMAN; METHODOLOGY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; REVIEW; SCIENCE; TOXICOLOGY;

ANIMALS; DECISION MAKING; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872243728     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011112-140159     Document Type: Review

References (81)

1. Frontline. 2002. Interview: Sidney Wolfe, M.D. WGBH-TV, Nov. 4. http://www.pbs.org/wgbh/pages/frontline/shows/prescription/interviews/wolfe.html
2. Roberts C. 2006. The FDA stands by dangerous drugs, do you? Doc Roberts, Oct. 11. http://www. docroberts.com/ar-20-c-16-the-fda-stands-by-dangerous- drugs-do-you.aspx
3. Forbes S. 2011. How the FDA may kill millions of us. Forbes, Feb. 14. http://www.forbes.com/forbes/2011/0214/opinions-steve-forbes-fact-comment-fda- may-kill-millions.html
4. Support of Science at the FDA, Before the Subcomm. on Oversight and Investigations, House Comm. on Energy and Commerce, US House of Representatives. 2008. (statement of AC von Eschenbach, Acting Commissioner of the US Food and Drug Administration) http://www.hhs.gov/asl/testify/2008/01/t20080129c.html
5. Hamburg MA. 2011. Advancing regulatory science. Science 331:987
6. Law MT. 2004. History of food and drug regulation in the United States. EH.net, Econ. Hist. Assoc., Feb. 4. http://eh.net/encyclopedia/article/Law.Food. and.Drug.Regulation
7. US Food Drug Admin. 2009. Centennial of FDA. US Food Drug Admin., May 13. http://www.fda.gov/AboutFDA/WhatWeDo/History/CentennialofFDA/default.htm
8. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. 1989. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 321:406-12
9. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. 1990. Torsades de pointes occurring in association with terfenadine use. JAMA 264:2788-90
10. Griffen L, Anchors M. 1998. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen.' Arch. Intern. Med. 158:102
11. Mirsalis JC. 1987. Genotoxicity, toxicity, and carcinogenicity of the antihistamine methapyrilene. Mutat. Res. 185:309-17
12. Bai JPF, Abernethy DR. 2013. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu. Rev. Pharmacol. Toxicol. 53:451-73
13. DuMouchel W. 1999. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53:177-90
14. Szarfman A, Machado SG, O'Neill RT. 2002. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25:381-92
15. Bottone FG Jr, Barry WT. 2009. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Curr. Med. Res. Opin. 25:1535-50
16. Motola D, Piccinni C, Biagi C, Raschi E, Marra A, et al. 2012. Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf. 35:315-23
17. SakaedaT,KadoyamaK,Okuno Y. 2011. Statin-associated muscular and renal adverse events: datamining of the public version of the FDA adverse event reporting system. PLoS ONE 6:e28124
18. US Food Drug Admin. 2012. FDA's Sentinel Initiative. US Food Drug Admin., Aug. 6. http://www. fda.gov/Safety/FDAsSentinelInitiative/default.htm
19. Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, et al. 2012. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol. Drug Saf. 21(Suppl. 1):9-11
20. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. 2011. Developing the Sentinel System-a national resource for evidence development. N. Engl. J. Med. 364:498-99
21. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, et al. 2012. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol. Drug Saf. 21(Suppl. 1):1-8
22. Furberg CD, Pitt B. 2001. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2:205-7
23. Woosley RL. 1990. CAST: implications for drug development. Clin. Pharmacol. Ther. 47(5):553-56
24. Hallstrom AP, Greene HL, Huther ML. 1991. The healthy responder phenomenon in non-randomized clinical trials. Stat. Med. 10:1621-31
25. Moore TJ. 1995. Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster. New York: Simon & Schuster
26. Nissen SE, Wolski K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356:2457-71
27. Mukherjee D, Nissen SE, Topol EJ. 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954-59
28. Agency Healthc. Res. Qual. 2008. Centers for Education and Research on Therapeutics (CERTs) overview: fact sheet. AHRQ publ. 08-P009-EF, Agency Healthc. Res. Qual., Rockville, MD. http://www.certs.hhs.gov/about/certsovr.htm
29. Woosley RL. 1998. Centers for education and research in therapeutics. Pharmacologist 40:69
30. WardellWM. 1978. The US Drug Efficacy Study and its implication (DESI). Agents Actions 8:421-22
31. Kraiczi H, Jang T, Ludden T, Peck CC. 2003. Randomized concentration-controlled trials: motivations, use, and limitations. Clin. Pharmacol. Ther. 74:203-14
32. Rowland M, Balant L, Peck C. 2004. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS J. 6:56-67
33. Lee H, Yim DS, Zhou H, Peck CC. 2005. Evidence of effectiveness: How much can we extrapolate from existing studies? AAPS J. 7:E467-74
34. Fattinger KE, Sheiner LB, Verotta D. 1995. A new method to explore the distribution of interindividual random effects in non-linear mixed effects models. Biometrics 51:1236-51
35. Shi J, Kovacs SJ, Wang Y, Ludden TM, Bhargava VO. 2005. Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J. Pharmacokinet. Pharmacodyn. 32:419-39
36. Rowland M, Peck C, Tucker G. 2011. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51:45-73
37. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3:711-15
38. US Dep. Health Hum. Serv., US Food Drug Admin., Cent. Drug Eval. Res., Cent. Biol. Eval. Res. 1999. Guidance for industry: population pharmacokinetics. Feb. 1999, US Food Drug Admin., Rockville, MD. http://www.fda.gov/downloads/ ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf
39. Lesko LJ, Atkinson AJ Jr. 2001. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41:347-66
40. Salerno RA, Lesko LJ. 2004. Pharmacogenomics in drug development and regulatory decision-making: the Genomic Data Submission (GDS) proposal. Pharmacogenomics 5:25-30
41. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ. 2006. Application of pharmacogenomics in clinical pharmacology. Toxicol. Mech. Methods 16:89-99
42. Lesko LJ. 2008. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84:301-3
43. Amur S, Frueh FW, Lesko LJ,Huang SM. 2008. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark. Med. 2:305-11
44. Gobburu JVS, Lesko LJ. 2009. Quantitative disease, drug, and trial models. Annu. Rev. Pharmacol. Toxicol. 49:291-301
45. Lesko LJ, Rowland M, Peck CC, Blaschke TF. 2000. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. J. Clin. Pharmacol. 40:803-14
46. Marroum P, Uppoor R, Parmelee T, Ajayi F, Burnett A, et al. 2000. In vivo drug-drug interaction studies-a survey of all new molecular entities approved from 1987 to 1997. Clin. Pharmacol. Ther. 68:280-85
47. Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW. 2007. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin. Pharmacol. Ther. 81:294-97
48. Goodsaid F, Frueh F. 2007. Biomarker qualification pilot process at theUSFood andDrugAdministration. AAPS J. 9:E105-8
49. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LRJ. 1992. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52:231-38
50. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. 1993. Effect of concomitant administration of cimetidine and ranitidine on the pharmacokinetics and electrocardiographic effects of terfenadine. Eur. J. Clin. Pharmacol. 45:41-46
51. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. 1993. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53:630-36
52. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. 1993. Terfenadineketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 269:1513-18
53. Honig PK, Wortham DC, Lazarev A, Cantilena LR. 1996. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J. Clin. Pharmacol. 36:345-51
54. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, et al. 1992. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:465-73
55. Rodriguez WJ, Roberts R, Murphy D. 2003. Current regulatory policies regarding pediatric indications and exclusivity. J. Pediatr. Gastroenterol. Nutr. 37(Suppl. 1):S40-45
56. Rodriguez W, Selen A, Avant D, Chaurasia C, Crescenzi T, et al. 2008. Improving pediatric dosing through pediatric initiatives: what we have learned. Pediatrics 121:530-39
57. Tauer CA. 2002. Central ethical dilemmas in research involving children. Account. Res. 9:127-42
58. Institute of Medicine. 1989. Training and Professional Support of Medical Reviewers at the Food and Drug Administration. Washington, DC: Natl. Acad. Press
59. USFood Drug Admin. 2004. Innovation or stagnation: challenge and opportunity on the critical path to new medical products.Chall. Oppor.Rep., March 2004, US Food Drug Admin., Silver Spring,MD. http://www.fda. gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm
60. Woosley RL, Myers RT, Goodsaid F. 2010. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin. Pharmacol. Ther. 87:530-33
61. US Dep. Health Hum. Serv., US Food Drug Admin., Cent. Drug Eval. Res. 2010. Guidance for industry: qualification process for drug development tools. Oct. 2010, US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf
62. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, et al. 2010. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat. Biotechnol. 28:455-62
63. Goodsaid F, Frueh F, Mattes W. 2007. The Predictive Safety Testing Consortium: a synthesis of the goals, challenges and accomplishments of the Critical Path. Drug Discov. Today Technol. 4:47-50
64. Usdin S. 2011. PDUFA: a lot of talk. BioCentury, June 6. http://www.biocentury.com/biotech-pharmanews/coverstory/2011-06-06/ its-about-meetings-not-money-a1
65. US Food Drug Admin. 2010. NIH and FDA announce collaborative initiative to fast-track innovations to the public. US Food Drug Admin., Feb. 24. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm201706.htm
66. US Food Drug Admin. 2008. FDA appoints Dr. Frank M. Torti to senior leadership position. US Food Drug Admin., Apr. 9. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116877.htm
67. US Food Drug Admin. 2011. Advancing regulatory science at FDA. Strateg. Plan, Aug. 2011, US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/ scienceresearch/specialtopics/regulatoryscience/ucm267719.htm
68. US Food Drug Admin. 2011. Driving biomedical innovation: initiatives to improve products for patients. Oct. 2011, US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM274464. pdf
69. US Food Drug Admin. 2011. FDA invests $2 million in partnerships through Centers of Excellence in Regulatory Science and Innovation. US Food Drug Admin., Oct. 26. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm277267.htm
70. US Food Drug Admin. 2012. Another counterfeit cancer medicine found in U.S.-illegal practice puts patients at risk. US Food Drug Admin., July 10. http://www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/ ucm298047.htm
71. Abernethy DR, Bai JP, Burkhart K, Xie HG, Zhichkin P. 2011. Integration of diverse data sources for prediction of adverse drug events. Clin. Pharmacol. Ther. 90:645-46
72. Dilts DM, Cheng SK, Crites JS, Sandler AB, Doroshow JH. 2010. Phase III clinical trial development: a process of chutes and ladders. Clin. Cancer Res. 16:5381-89
73. McGinnis JM. 2010. Evidence-based medicine-engineering the Learning Healthcare System. Stud. Health Technol. Inform. 153:145-57
74. Tyer D. 2011. Digital Pharma: Pfizer's mobile-powered 'virtual' clinical trial. InPharm, Aug. 6. http://www.inpharm.com/news/159024/digital-pharma- pfizer-virtual-clinical-trial
75. US Food Drug Admin. 2005. Drug-diagnostic co-development concept paper. US Food Drug Admin., Silver Spring, MD. http://www.fda.gov/downloads/Drugs/ ScienceResearch/ResearchAreas/Pharmacogenetics/UCM116689.pdf
76. Woosley RL. 2012. Is it possible for FDA regulatory scientists and industry scientists to work together? Clin. Pharmacol. Ther. 91:390-92
77. Clinical Data Interchange Standards Consortium (CDISC). 2012. CDISC, C-Path and FDA collaborate to develop data standards to streamline path to new therapies. CDISC, June 21. http://www.cdisc.org/content5571
78. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009. 2009 Biospecimen Research Network Symposium: advancing cancer research through biospecimen science. Cancer Res. 69:6770-72
79. Mattsson N, Blennow K, Zetterberg H. 2010. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: United we stand, divided we fall. Clin. Chem. Lab. Med. 48:603-7
80. Insel TR. 2012. Invited response to: Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin. Transl. Sci. 5:130-31
81. US Food Drug Admin. 2011. FDA-CMS Parallel Review. US Food Drug Admin., Oct. 11. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ HowtoMarketYourDevice/PremarketSubmissions/ucm255678.htm